Carter, P. J. & Rajpal, A. Designing antibodies as therapeutics. Cell 185, 2789–2805 (2022).
Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585–608 (2019).
Chen, S. W. & Zhang, W. Current trends and challenges in the downstream purification of bispecific antibodies. Antib. Ther. 4, 73–88 (2021).
Atwell, S., Ridgway, J. B., Wells, J. A. & Carter, P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 270, 26–35 (1997).
Choi, H. J., Kim, Y. J., Lee, S. & Kim, Y. S. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol. Cancer Ther. 12, 2748–2759 (2013).
De Nardis, C. et al. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G(1). J. Biol. Chem. 292, 14706–14717 (2017).
Gramer, M. J. et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. MAbs 5, 962–973 (2013).
Gunasekaran, K. et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637–19646 (2010).
Igawa T. H. & Tsunoda, H. Process for production of polypeptide by regulation of assembly. WO patent WO/2006/106905 (2006).
Labrijn, A. F. et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc. Natl Acad. Sci. USA 110, 5145–5150 (2013).
Merchant, A. M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677–681 (1998).
Moore, G. L. et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 3, 546–557 (2011).
Ridgway, J. B., Presta, L. G. & Carter, P. Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617–621 (1996).
Strop, P. et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J. Mol. Biol. 420, 204–219 (2012).
Von Kreudenstein, T. S. et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs 5, 646–654 (2013).
Moore, G. L. et al. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats. Methods 154, 38–50 (2019).
Murphy, A. J. et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc. Natl Acad. Sci. USA 111, 5153–5158 (2014).
Bonisch, M. et al. Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies. Protein Eng. Des. Sel. 30, 685–696 (2017).
Cooke, H. A. et al. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies. MAbs 10, 1248–1259 (2018).
Schaefer, W. et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl Acad. Sci. USA 108, 11187–11192 (2011).
Wu, X. et al. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. MAbs 7, 364–376 (2015).
Dillon, M. et al. Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. MAbs 9, 213–230 (2017).
Lewis, S. M. et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat. Biotechnol. 32, 191–198 (2014).
Liu, Z. et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J. Biol. Chem. 290, 7535–7562 (2015).
Mazor, Y. et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 7, 377–389 (2015).
Surowka, M., Schaefer, W. & Klein, C. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs 13, 1967714 (2021).
Lariviere, L. et al. End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations. Int J. Pharm. X 5, 100157 (2023).
Biswas, E. R. Selective secretion of circulating antibodies in the milk of the rat. Nature 192, 883–884 (1961).
Feige, M. J. et al. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol. Cell 34, 569–579 (2009).
Lilie, H., Lang, K., Rudolph, R. & Buchner, J. Prolyl isomerases catalyze antibody folding in vitro. Protein Sci. 2, 1490–1496 (1993).
Preisendörfer, S., et al. FK506-binding protein 11 is a novel plasma cell-specific antibody folding catalyst with increased expression in idiopathic pulmonary fibrosis. Cells 11, 1341.
Beverley, P. C., Linch, D. & Callard, R. E. Human Leucocyte antigens. Haematol. Blood Transfus. 26, 309–313 (1981).
Goldenberg, M. M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21, 309–318 (1999).
Luo, J. et al. Coevolution of antibody stability and Vκ CDR-L3 canonical structure. J. Mol. Biol. 402, 708–719 (2010).
Matsumiya, S. et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368, 767–779 (2007).
Choi, H. J., Seok, S. H., Kim, Y. J., Seo, M. D. & Kim, Y. S. Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation. Mol. Immunol. 65, 377–383 (2015).
McLarty, K. et al. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur. J. Nucl. Med. Mol. Imaging 36, 81–93 (2009).
Cho, H. S. et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756–760 (2003).
Abdiche, Y. N. et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs 7, 331–343 (2015).
Kuick Research. Bispecific antibody market opportunity, drug dosage, patent, price, sales & clinical trials insight 2030. GlobeNewswire https://www.globenewswire.com/news-release/2025/03/12/3041385/28124/en/Bispecific-Antibody-Market-Opportunity-Drug-Dosage-Patent-Price-Sales-Clinical-Trials-Insight-2030-New-Report-Highlights-600-Bispecific-Antibodies-in-Clinical-Trials-Worldwide.html (2025).
Behnke, J., Mann, M. J., Scruggs, F. L., Feige, M. J. & Hendershot, L. M. Members of the Hsp70 family recognize distinct types of sequences to execute ER quality control. Mol. Cell 63, 739–752 (2016).
Knarr, G., Gething, M. J., Modrow, S. & Buchner, J. BiP binding sequences in antibodies. J. Biol. Chem. 270, 27589–27594 (1995).
Marcinowski, M. et al. Conformational selection in substrate recognition by Hsp70 chaperones. J. Mol. Biol. 425, 466–474 (2013).
Cooper, P. R. et al. The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups. Front Pharm. 5, 225 (2014).
Feige, M. J., Hagn, F., Esser, J., Kessler, H. & Buchner, J. Influence of the internal disulfide bridge on the folding pathway of the CL antibody domain. J. Mol. Biol. 365, 1232–1244 (2007).
Micsonai, A. et al. Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy. Proc. Natl Acad. Sci. USA 112, E3095–E3103 (2015).
Kabsch, W. XDS. Acta Crystallogr D 66, 125–132 (2010).
Evans, P. Scaling and assessment of data quality. Acta Crystallogr D 62, 72–82 (2006).
Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr D 69, 1204–1214 (2013).
Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D 67, 293–302 (2011).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D 66, 213–221 (2010).
Frank, M., Walker, R. C., Lanzilotta, W. N., Prestegard, J. H. & Barb, A. W. Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J. Mol. Biol. 426, 1799–1811 (2014).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D 66, 486–501 (2010).
Liu, D. et al. Assignment of 1H, 13C and 15N resonances of the reduced human IgG1 C(H)3 domain. Biomol. NMR Assign. 1, 93–94 (2007).
Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995).
Lee, W., Tonelli, M. & Markley, J. L. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy. Bioinformatics 31, 1325–1327 (2015).
Kaliss, N. & Pressman, D. Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins. Proc. Soc. Exp. Biol. Med. 75, 16–20 (1950).
Choi, W. S. et al. Crystal structure of the ProAla Fc. Protein Data Bank https://doi.org/10.2210/pdb9mvx/pdb (2025).
Choi, W. S. et al. Crystal structure of the ProAla Fab. Protein Data Bank https://doi.org/10.2210/pdb9N8Q/pdb (2025).
